Programme

Jump to start of Day Two

Day One: 27th March 2007
08:30		Delegate registration
09:00	Rajesh Chavhan Senior Financial Analyst NOVARTIS PHARMA	Opening remarks from the chair
Budgeting and Planning: looking to the future
09:10	Peter Potter-Lesage Chief Financial Officer MEDICINES FOR MALARIA VENTURE (MMV)	Defining the finance function of a not-for-profit public-private partnership Key finance strategies for alliances with major pharma companies and academia Corporate Social Responsibility and in-kind investments The importance of fundraising and risk mitigation
09:50	Annegret Gloeckner Partner PRICEWATERHOUSECOOPERS	Different factors affecting the outcome of revenue reporting The impact of licensing arrangements Product liability and drug pricing in revenue recognition The importance of measuring contract stage revenue How the reimbursement system be utilised in revenue reporting
10:30		Morning break
11:00	Adrian Gardner Finance Director PROSTRAKAN	Revenue recognition: implementing the key factors Key elements to include in the balance sheet How capitalised revenue is recognised over different time periods The impact of licensing arrangements
Tax: strategies for efficient tax planning
11:40	Gianmarco Monsellato Managing Partner TAJ (a member of DELOITTE TOUCHE TOHMATSU)	Tax audits: key concerns for pharma The importance of Sarbanes-Oxley compliance in a global environment Understanding the tax implications arising from cross-border deals
12:20	Richard Fletcher Senior Director Corporate Tax Department BAKER & MCKENZIE	Maximising tax efficiencies in pharmaceuticals through inter company financing Reducing the tax base post transfer pricing and post intangible planning Achieving acceptable levels of debt in your organisations by country Cost pooling considerations as a tool in cross border management of pharmaceuticals
13:00		Lunch
Pricing regulations: special transfer pricing
14:00	Guy A Kersch Senior Transfer Pricing CounselGRANT THORNTON UK LLP (Luxembourg); previously Tax Counsel Europe PFIZER	Special transfer pricing and the ever increasing regulation involved The need for special transfer pricing in a competitive environment Understanding how governments are seeking to stem the flow of tax overseas Ensuring best practise for transfer pricing in a multi-national company
14:40	Led by Karl Wündisch former corporate officer SCHERING AG The Panel: Dr. Ted Keen Vice President Transfer Pricing The Ballentine Barbera Group Guy A Kersch Senior Transfer Pricing Counsel GRANT THORNTON UK LLP (Luxembourg); previously Tax Counsel Europe PFIZER Chris Smith Senior Manager Grant Thornton UK LLP	Moving Target: Impact for bio-pharmaceuticals’ arm’s length prices from changeover to IFRS accounting ?
15:20		Afternoon break
15:40	Rajesh Chavhan Senior Financial Analyst NOVARTIS PHARMA	Shared services: creating added value to your company Understanding the correct areas in which it should be used Realising the correct strategies for maintaining control How company strategies can be aligned to ensure compliance What risk minimisation programs can be put in place?
16:20	Steve Moss Senior Advisor EquaTerra	Shared services and M&A: a complimentary match How shared services and organic growth develop the financial planning of a company The reasons that Financial & Accounting Outsourcing (FAO) can support a company strategy Lessons that can learned from other industries
17:00		Closing remarks from the chair and end of day one

Jump to start of Day One
Day Two: 28th March 2007
08:30		Delegate registration
09:00		Opening remarks from the chair
Mergers & Acquisitions: broadening your horizons
09:10	Darryl Conley Associate Principal Everest group	Outsourcing in Pharma: what we can expect for the future Pharma today in relation to outsourcing of all ITO vs BPO activity globally What FAO is being outsourced and what are the apparent drivers in Pharma FAO? Why are the conditions now right for FAO in pharma?
09:50	Marc Voigt CFO MEDICAL ENZYMES	Deal structuring: correctly aligning your business for a new era How you can ensure that business technologies are correctly aligned Maintaining data security throughout a merger Monitoring the rapid expansion that can occur with M&A Best practise methods for merging two or more separate accounting systems
10:30	Isabelle Rege Global Head of Financial Reporting & Accounting SANDOZ	Main challenges for the Financial Reporting & Accounting organisation arising from the integration of a newly acquired business Year 1: getting the basics right Year 2: dealing with some real issues Year 3: strengthening the organization
11:10		Morning break
Private to Public: what does the shareholder want?
11:40	David Smith CFO GALAPAGOS	First steps for a BioTech after an Initial Public Offering (IPO) Maximizing Investor Relations with limited resource Examples on how to use the listed stock creatively in M&A Factors which may impact whether the IPO proves to be a curse or a blessing
12:20	Jo Walton Managing Director Healthcare Research LEHMAN BROTHERS	All change: moving from a private to a public company Dealing with shareholders and joint ventures The key challenges faced and ensuring that financial strategies are aligned Realising how financial accounting methods need to change and develop with this move
13:30		Lunch
14:00		Roundtable afternoon led by KPMG Delegates will be able to attend two hour long round-table discussion groups from a selection of four key topics, punctuated by a half hour break at 15:00. An industry expert will facilitate each session ensuring an exchange of opinions and essential experiences related to an aspect of finance and accounting
	Karen Witton Director, Indirect Tax Markus Wyss Senior Manager, Head of Global Transfer Pricing, Switzerland	Table 1: Tax and transfer pricing
	Peter Berweger Partner, Transaction Services Roman Hermann Manager, Head Valuations Switzerland	Table 2: M&A: how to deal with purchase price allocation
	Stephen Oxley European Chair, KPMG's Pharmaceuticals Practice	Table 3: IFRS: the key issues and how it has affected company operations
	Dr. Andreas Boller Senior Manager, Restructuring & Performance Services	Table 4: Operations & Supply Chain: Interactions with Finance & Accounting
17:00		Closing remarks from the chair and end of conference